Novartis Venture Fund
The Novartis Venture Fund is dedicated to fostering innovation in the life sciences sector, with a mission to drive significant patient benefits and generate superior returns. The fund invests in biotechnology and biopharmaceutical companies at various stages of growth, managing over USD 750 million in committed capital across more than 40 portfolio companies in North America and Europe. The fund focuses on developing novel therapeutics and platforms to address unmet patient needs globally.
Novartis Venture Fund
Portfolio
Developing medicines for hard-to-treat diseases using next-generation targeted protein degradation approaches.
#Platform
Developing large-molecule therapeutics to treat arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D).
#Cardiovascular
Focused on correcting disrupted brain physiology to treat neurodegenerative disease.
#Neuroscience
Developing innovative immunotherapies to transform the tumor microenvironment and improve treatment options for cancer patients.
#Oncology
Dedicated to the research and development of novel therapies for the treatment of respiratory diseases.
#Respiratory
Developing small-molecule enzyme inhibitors that target distal binding pockets to reprogram enzyme activity with a focus on high-value oncology indications.
#Oncology, Platform
Pursuing the vast potential of small molecule medicines for RNA-mediated diseases.
#Platform, Muscular, Neuroscience
Inserting therapeutic genes precisely and durably into safe harbor sites in the human genome.
#Not specified
Focuses on the development of novel anti-cancer therapies by drugging molecular targets essential for cancer cells undergoing DNA replication stress.
#Oncology
Developing NMDA/TRPM4 interface inhibitors to stop neurodegeneration, restore function, and maintain brain health.
#Neuroscience
Engineers T cells to generate stable, scalable, IL2 and tissue targeted regulatory T cells better suited to address serious unmet medical needs for autoimmunity, alloimmunity, and autoinflammation.
#Immunology
Developing small-molecule covalent inhibitors targeting non-cysteine amino acids to address current challenges associated with many disease targets, including selectivity, druggability, and resistance.
#Platform
Employs a single-cell genomics platform to dissect the biology of immune cells in human tumors and deliver meaningful clinical improvements.
#Immunology, Oncology
Focusing on targeting DNA damage repair pathways to effectively treat Huntington’s and other triplet repeat diseases.
#Neuroscience
Developing first-in-class therapeutics to protect and improve the vision of patients with retinal disease.
#Ophthalmology
Developing a first-in-class series of anti-cancer molecular glues that reactivate protein phosphatase 2A (PP2A).
#Oncology
Developing breakthrough medicines to exploit cancer’s vulnerabilities in gene expression.
#Oncology
Develops first-in-class therapeutics to target novel enzyme families activated under cellular stress conditions that contribute to disease.
#Immunology
Exploiting protein splicing to develop the next generation of gene therapies for the treatment of inherited eye diseases.
#Gene Therapy, Platform
Developing a new standard of care for patients suffering from severe diseases including cancer.
#Platform, Oncology
Developing an IgA therapeutic monoclonal antibody platform to activate neutrophils for the treatment of solid tumors.
#Oncology, Immunology
Focuses on the discovery and clinical development of gene therapy and protein replacement therapy for inherited metabolic liver diseases.
#Gene Therapy
Key People
Managing Director
Managing Director
Managing Director
Principal
Managing Director
Analyst